Tirbanibulin Mesylate NEW
| Price | $32 | $51 | $64 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Tirbanibulin Mesylate | CAS No.: 1080645-95-9 |
| Purity: 99.42% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Tirbanibulin Mesylate |
| Description | Tirbanibulin Mesylate (KX01 Mesylate) is an inhibitor of Src that targets the peptide substrate site of Src (GI50: 9-60 nM in cancer cell lines). |
| In vitro | Tirbanibulin Mesylate is found to inhibit certain leukemia cells that are resistant to current commercially available drugs, such as those derived from chronic leukemia cells with the T3151 mutation. Tirbanibulin Mesylate displays steep dose-response curves against Huh7 (GI50=9 nM), PLC/PRF/5 (GI50=13 nM), Hep3B (GI50=26 nM), and HepG2 (GI50=60 nM), four hepatic cell cancer (HCC) cell lines [1]. Tirbanibulin Mesylate is evaluated in engineered Src drove cell growth assays inNIH3T3/c-Src527F and SYF/c-Src527F cells and exhibits GI50 with 23 nM and 39 nM, respectively [2]. |
| In vivo | In pre-clinical animal models of cancer, Tirbanibulin Mesylate (p.o.) is shown to inhibit primary tumor growth and to suppress metastasis [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 99 mg/mL (187.63 mM), Sonication is recommended. |
| Keywords | KX01 | KX-01 Mesylate | KX2-391 | Src | KX 01 Mesylate | Inhibitor | inhibit | KX-01 | Tirbanibulin | KX 01 | Microtubule/Tubulin | Tirbanibulin Mesylate |
| Inhibitors Related | Flubendazole | Nintedanib | Mebendazole | N-Phenylbenzylamine | 4-Isopropoxybenzoic acid | Oxfendazole | Ibrutinib | Thiabendazole | Methylene Blue | Methylene Blue trihydrate | Paclitaxel | 4'-Demethylepipodophyllotoxin |
| Related Compound Libraries | Bioactive Compound Library | EMA Approved Drug Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Microtubule-Targeted Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $33.00/2mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $0.00/10g |
VIP6Y
|
Zison Pharmaceutical (Shandong) Co., Ltd.
|
2024-05-24 | |
| $40.00/1kg |
VIP1Y
|
Hebei Zhuanglai Chemical Trading Co.,Ltd
|
2024-05-17 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY